GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » 14-Day RSI

XBIO (Xenetic Biosciences) 14-Day RSI : 45.33 (As of Dec. 15, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-15), Xenetic Biosciences's 14-Day RSI is 45.33.

The industry rank for Xenetic Biosciences's 14-Day RSI or its related term are showing as below:

XBIO's 14-Day RSI is ranked worse than
51.21% of 1523 companies
in the Biotechnology industry
Industry Median: 44.97 vs XBIO: 45.33

Competitive Comparison of Xenetic Biosciences's 14-Day RSI

For the Biotechnology subindustry, Xenetic Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's 14-Day RSI falls into.



Xenetic Biosciences  (NAS:XBIO) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xenetic Biosciences  (NAS:XBIO) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Xenetic Biosciences 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenetic Biosciences Business Description

Traded in Other Exchanges
N/A
Address
945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Executives
Grigory G. Borisenko director 40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov director C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow officer: Chief Financial Officer C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks director C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc 10 percent owner 25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110

Xenetic Biosciences Headlines

From GuruFocus